Samar Elshazly

Samar Elshazly

Auto-generated profile, based on publicly available information

Samar Elshazly


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2023 in Egyptian Journal of Medical Human Genetics
Verified
Journal Article
Open access
PDF file
RNReem Nabil
Reem Nabil
SESamar S. Elshazly
Samar S. Elshazly
NHNaglaa M. Hassan
Naglaa M. Hassan
HNHend A. Nooh
Hend A. Nooh
Background: Acute myeloid leukemia (AML) is a cancer of hematopoietic progenitors characterized by gene mutations. The most popular deregulations are mutation and altered expression in the p53 gene, which is considered the guardian of the genome. Its activity is controlled by regulatory genes, e.g., alternate open reading frame (ARF), whose defects could affect p53 activity. Aim: To study the effect of altered expression of p53 and ARF genes in de novo AML patients and correlate the results to the patients’ characteristics and outcomes. Methods: Expression levels of p53 and ARF were assessed in 96 AML adult patients compared to 20 healthy controls using quantitative reverse-transcription PCR (RT-qPCR). Results: There was significant up-regulation of p53 [77.6 (3.8–9528.3)] compared to controls [1.031 (0.210–9.051)], p < 0.001]. The expression level of ARF was significantly upregulated [6.2 (0.5–964.0)] compared to controls [0.854 (0.357–2.519), p < 0.001]. All of the low ARF expressers had low p53 overexpression, 61.1% of patients with high ARF expression had high p53 over-expression, and 38.9% with high ARF expression had low p53 over-expression (p < 0.001). ARF expression shows a trend of association with FLT3 mutation, as 89.3% with FLT3 mutation have high ARF expression (p = 0.080). Low p53 over-expression was seen in 77% of APL patients, while high p53 expression was associated with non-APL (p = 0.040). The median DFS of mutant NPM1 patients was higher than wild NPM1 (46.15 vs. 5.89 days, p = 0.045). Patients aged ≤ 50 years had better OS and DFS than those > 50 (p = 0.05, p = 0.035, respectively).There were no significant statistical associations between DFS and p53, ARF, and FLT3 mutations. Conclusion: The p53 and ARF genes are overexpressed in de novo AML patients and they are interrelated. low p53 overexpression is associated with APL phenotype and t(15;17) and patients with t(15;17) had slightly better survival than patients with negative t(15;17) (p = 0.061). AML patients with mutated NPM1 had better DFS than wild NPM1 (p = 0.045). p53 pathway regulation can occur by many alternative ways rather than gene mutation.

1 January 2024 in The Egyptian Journal of Hospital Medicine
Verified
Journal Article
Open access
PDF file
SESamar Elshazly
Samar Elshazly
AAAsmaa Abobakr
Asmaa Abobakr
HNHend Nooh
Hend Nooh
Background: Nucleophosmin 1 (NPM1) gene is known for its regulatory role of the ARF-p53-tumor suppressor pathway. Its mutations are known to be the most common gene mutations in AML. Aim: To detect the type of NPM1 gene mutation (NPM-A mut and non-A mut) in AML patients and correlating it with changes in molecular gene expression level of p53 and ARF genes also to study their relation to clinical, laboratory data and response to treatment. Methods: Absolute quantification of the NPM1 mutation type and the expression level of p53 and ARF genes were assessed using quantitative reverse-transcription PCR (RT-qPCR). Results: We studied 41 newly diagnosed AML patients, all of them had NPM1 gene mutation, out of them 25/41 had non-A mutation (61%) and 16/41 (39%) had mutation A. A statistically significant difference between AML patients with NPM1 mutation-A and non-A mutation was found in bone marrow blasts count (p-value=0.032). A trend statistical significance was observed in patients with NPM1 mutation-A and P53 gene overexpression than in patients with non-A mutation as well as ARF gene expression for patients with NPM1 mutation-A is higher than patients with non-A mutation (p-value=0.063). Median follow up of patients’ cohort was 1.81 (0.03-47.1) months. Median survival duration for patients carrying NPM1 mutation-A compared to those with other NPM1 mutations was 1.09 months versus 1.05 months, and this variation lacked statistical significance (p-value of 0.634). Conclusion: We can conclude that there is a trend statistically association between p53 and ARF genes high expression level and NPM1 mut-A type. It is important to detect the type of NPM1 mutation with examination of P53 and ARF genes expression to help in therapeutic strategies.

1 October 2024 in The Egyptian Journal of Hospital Medicine
Verified
Journal Article
Open access
PDF file
SESamar Elshazly
Samar Elshazly
HNHend Nooh
Hend Nooh
AAAsmaa Aboubakr
Asmaa Aboubakr
GNGhada Nabil
Ghada Nabil
Background: Essential thrombocythemia (ET) with Primary Myelofibrosis (PMF) and finally Polycythaemia Vera (PV), are considered the three main entities of the Philadelphia-negative MPNs. Mutations in JAKII, together with CALR and Myeloproliferative Leukemia Protein (MPL) genes can be detected in most of cases with Philadelphia-negative MPNs. The discovery of CALR mutations was implicated in better understanding of the molecular mechanisms involved in the pathogenesis of MPNs patients who had no mutations in JAKII or MPL genes. Patients and methods: The current study included 56 participants diagnosed with MPNs. Bone marrow trephine biopsy (BMB) was the sample of choice in our study. CALR specific monoclonal antibody (CAL2) by IHC was done for all MPN patients on BMB specimens. Results: Nearly 82 % of our cases (46/56) were positive for CALR mutation by IHC with sensitivity of 96.4%, and specificity of 88.9%, with positive predictive value of 94.7%, while negative predictive value was 92.3%, and total accuracy of CALR was 93.9%. We found a significant association between JAKII mutation and CALR positive patients (p=0.004) hyper cellular marrow was prevailing in CALR positive patients (p= 0.004). In addition, CALR mutant patients were associated significantly with higher degrees of fibrosis grade III & IV (p= 0.044). However, no significant relation between splenomegaly and CALR positivity was detected in our study. Conclusion: CAL2 by IHC was a sensitive and specific marker in detecting CALR mutation in patients diagnosed as MPN. Moreover, it was readily available and cost effective than other routine molecular techniques used in detecting such mutation.